Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | FABP6 | P51161 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13039642 | 0.83 | CYP19A1 (0.63) | CYP19A1ACHEFABP6AKR1B1KDM4E | |
| SCHEMBL13417489 | 0.81 | CYP19A1 (0.61) | CYP19A1ACHEKDM4EMAOB | |
| SCHEMBL24221827 | 0.80 | ACHE (0.48) | CYP19A1ACHEFABP6AKR1B1KDM4E | |
| SCHEMBL5648955 | 0.80 | CYP19A1 (0.60) | CYP19A1ACHEFABP6AKR1B1KDM4E | |
| SCHEMBL20165992 | 0.80 | CYP19A1 (0.60) | CYP19A1ACHEFABP6AKR1B1KDM4E | |
| SCHEMBL13384313 | 0.76 | TDP1 (0.47) | CYP19A1ALDH1A1 | |
| SCHEMBL768947 | 0.75 | CYP19A1 (0.59) | CYP19A1ACHEMAOB | |
| SCHEMBL15147097 | 0.75 | CYP19A1 (0.59) | CYP19A1ACHEMAOB | |
| SCHEMBL13197603 | 0.73 | ACHE (0.42) | CYP19A1ACHE | |
| SCHEMBL13197594 | 0.73 | ACHE (0.42) | CYP19A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-10270038-B2 | Fullerene derivative, organic solar cell using same, and preparation method therefor | LG CHEM, LTD. (KR) | 2019-04-23 | — | — | US | disclosed |
| WO-2018092921-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-24 | — | — | WO | disclosed |
| US-20160329499-A1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND PREPARATION METHOD THEREFOR | LG CHEM, LTD. (KR) | 2016-11-10 | — | — | US | disclosed |
| US-20160329499-A1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND PREPARATION METHOD THEREFOR | LG CHEM, LTD. (KR) | 2016-11-10 | — | — | US | disclosed |
| US-4992564-A | Preparation of 6-substituted 4-chromanones | MALLINCKRODT, INC. (US) | 1991-02-12 | — | — | US | disclosed |
| US-4918203-A | Preparation of 6-substituted 4-chromanones | MALLINCKRODT INC. | 1990-04-17 | — | — | US | disclosed |
| EP-0228172-B1 | PREPARATION OF 6-SUBSTITUTED 4-CHROMANONES | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0228172-A1 | Preparation of 6-substituted 4-chromanones | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160329499-A1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND PREPARATION METHOD THEREFOR | WEE2, WEE1, STOML2 | CYP19A1 963/4885ACHE 2690/4885FABP6 2011/4885 |
| US-10270038-B2 | Fullerene derivative, organic solar cell using same, and preparation method therefor | WEE2, WEE1, STOML2 | CYP19A1 963/4885ACHE 2690/4885FABP6 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.